J&J to ship children’s medicine amid House committee hearing
WASHINGTON Johnson & Johnson said Wednesday that it plans to ship limited quantities of one of its children’s medicines following a nationwide recall.
J&J CEO William Weldon said nearly 1 million bottles of the medicine — which he did not disclose — will be available for release next week. The drug maker met with the House Committee on Oversight and Government Reform on Thursday to examine the circumstances surrounding J&J’s recall of more than 135 million bottles of infant and children’s medicines produced by Johnson & Johnson/McNeil Consumer Healthcare, including children’s Tylenol, infant’s Tylenol, children’s Motrin and children’s Benadryl.
On Sept. 16, J&J’s consumer group chair Colleen Goggins said she would retire from her post on March 1, 2011.
HerbaSway introduces Last Round to cap off night
WALLINGFORD, Conn. HerbaSway has introduced a hangover support in a ready-to-drink single “shot.”
Last Round is a 2.5-oz. bottle that contains such ingredients as kudzu root, stevia and green tea extracts. Last Round works by removing the effects of alcohol, “relaxing” the flow of blood and oxygen to the brain, and detoxifying the body so users avoid headaches, dry mouth and other ailments associated with hangovers, the company said. HerbaSway also recommended drinking one 2.5-oz. bottle of Last Round just before bedtime.
“Our whole philosophy at HerbaSway revolves around living a natural lifestyle, and as a natural hangover support, Last Round fits perfectly alongside our other product lines,” said Robert Wolfson, president of HerbaSway. “Drinking moderately and responsibly also fits into our philosophy, but we recognize that there are times when people go a little overboard. On these occasions, a final shot of Last Round provides protection against hangovers the next day. As we say on the bottle, it’s the best way to end a night of drinking.”
Last Round is available online and at retail shops nationwide, including Whole Foods. It is sold in two-packs, six-packs, 12-packs and party packs of 50 bottles.
Oncologists favor biosimilar adoption, Decision Resources finds
BURLINGTON, Mass. While biosimilars promise to provide therapies for a wide range of diseases, their biggest fans may come from cancer specialists, according to a new report.
Healthcare market research firm Decision Resources found in a report that oncologists would be the most aggressive in adopting biosimilars compared with other specialists because of their lower clinical trial requirements. According to research, oncologists in the United States will adopt biosimilars faster than their European counterparts because they will require fewer and shorter phase-3 clinical trials before they feel comfortable prescribing them.
The firm expected biosimilars of granulocyte colony-stimulating factor, as well as biosimilars of monoclonal antibody therapies used to treat cancer, to reduce brand sales by more than $7 billion in 2019 in the United States, Japan, the United Kingdom, France, Germany, Italy and Spain, which Decision Resources collectively refers to as the “EU5.”
“Because of patent expiries and more-established regulatory pathways for approving biosimilars in Europe, most biosimilar [monoclonal antibodies] will launch in the EU5 before the United States,” Decision Resources analyst Cindy Fung said. “As a result, U.S. physicians will likely benefit from clinical experience in European markets that will increase their rate of adopting these agents.”